Crossmark

Targeting sphingolipid metabolism with the sphingosine kinase inhibitor SKI-II overcomes hypoxia-induced chemotherapy resistance in glioblastoma cells: effects on cell death, self-renewal, and invasion

Crossref DOI link: https://doi.org/10.1186/s12885-023-11271-w

Published Online: 2023-08-16

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sousa, Nadia

Geiß, Carsten

Bindila, Laura

Lieberwirth, Ingo

Kim, Ella

Régnier-Vigouroux, Anne
Funding

Funding for this research was provided by:

Johannes Gutenberg-Universität Mainz
License Information

Text and Data Mining valid from 2023-08-16

Version of Record valid from 2023-08-16
More Information

Article History

Received: 12 October 2022

Accepted: 7 August 2023

First Online: 16 August 2023

Declarations

:

: In the study, there was NO direct involvement of humans; tissues have not been removed from human patients for the current study purpose.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below